Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Melanoma 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia, Myeloid, Chronic-Phase 3Polycythemia Vera 2Neoplasm Metastasis 2Carcinoma, Renal Cell 2Uveal Melanoma 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocythemia, Essential 1Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Recurrence 1Primary Myelofibrosis 1Osteosarcoma 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neurofibroma 1Neoplasms 1Metastatic Gastrointestinal Carcinoid Tumor 1Lymphoma, Non-Hodgkin 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia 1Kidney Neoplasms 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Graft vs Host Disease 1Glioma 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Squamous Cell 1Carcinoma, Hepatocellular 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × peginterferon alfa-2b × Clear all
NCT02634294 2023-03-16

Peg Interferon α-2b for Relapsed Hematological Malignancies After Allo-HSCT

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Phase 2/3 Completed
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡